Expressions of Matrix Metalloproteinase-7 and Matrix Metalloproteinase-14 Associated with the Activation of Extracellular Signal-regulated Kinase1/2 in Human Brain Gliomas of Different Pathological Grades

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2010 Sep 3

PMID 20809186

Citations 8

Authors

Hui Xie

Yi-xue Xue

Li-Bo Liu

Ping Wang

Yun-Hui Liu

Hao-qiang Ying

Affiliations

Soon will be listed here.

Abstract

The purpose of this study is to determine whether the expressions of MMP-7 and MMP-14 are associated with the ERK 1/2 signaling pathway in human brain gliomas of different pathological grades. Immunohistochemistry and western blot methods were used to determine the expressions of MMP-7, MMP-14 and the phosphorylation status of ERK1/2 in 73 cases of human brain glioma specimens and two cases of normal brain tissues. Results indicated that the protein expression levels of MMP-7, MMP-14 and ERK1/2 phosphorylation level were all elevated with the increasing pathological grades in brain glioma tissues, and correlation assay indicated that the level of ERK1/2 phosphorylation was positively correlated with protein expression levels of MMP-7 and MMP-14 in gliomas of different pathological grades respectively. Moreover, the impact of ERK1/2 inhibitor U0126 on the expressions of MMP-7 and MMP-14 was examined in human U87 glioma cells by western blot analysis. The expressions of MMP-7 and MMP-14 were significantly decreased in human U87 glioma cells after treatment with ERK1/2 inhibitor U0126. The above results suggest that the expressions of MMP-7 and MMP-14 may be associated with activation of ERK1/2 signaling pathway in human brain gliomas of different pathological grades.

Citing Articles

Screening MT1-MMP Activity and Inhibition in Three-Dimensional Tumor Spheroids.

Knapinska A, Drotleff G, Chai C, Twohill D, Ernce A, Tokmina-Roszyk D Biomedicines. 2023; 11(2).

PMID: 36831098 PMC: 9953393. DOI: 10.3390/biomedicines11020562.

MT1-MMP Expression Levels and Catalytic Functions Dictate LDL Receptor-Related Protein-1 Ligand Internalization Capacity in U87 Glioblastoma Cells.

Pratt J, Haidara K, Annabi B Int J Mol Sci. 2022; 23(22).

PMID: 36430705 PMC: 9692856. DOI: 10.3390/ijms232214214.

Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.

Zhang B, Xu C, Liu J, Yang J, Gao Q, Ye F Aging (Albany NY). 2021; 13(6):9085-9107.

PMID: 33735110 PMC: 8034893. DOI: 10.18632/aging.202789.

Effects of ERK1/2 S-nitrosylation on ERK1/2 phosphorylation and cell survival in glioma cells.

Jin L, Cao Y, Zhang T, Wang P, Ji D, Liu X Int J Mol Med. 2017; 41(3):1339-1348.

PMID: 29286066 PMC: 5819938. DOI: 10.3892/ijmm.2017.3334.

Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.

de Lucas A, Schuhmacher A, Oteo M, Romero E, Camara J, De Martino A PLoS One. 2016; 11(7):e0158634.

PMID: 27462980 PMC: 4962974. DOI: 10.1371/journal.pone.0158634.

References

Ichikawa Y, Ishikawa T, Momiyama N, Hasegawa S, Fujii S, Saito S . [Function of MMP-7 in colorectal cancer]. Nihon Rinsho. 2003; 61 Suppl 7:209-14. View

Kim J, Choi C, Benveniste E, Kwon D . TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem Biophys Res Commun. 2008; 377(1):195-9. DOI: 10.1016/j.bbrc.2008.09.095. View

Ma Z, Qin H, Benveniste E . Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol. 2001; 167(9):5150-9. DOI: 10.4049/jimmunol.167.9.5150. View

Lopez-Gines C, Gil-Benso R, Benito R, Mata M, Pereda J, Sastre J . The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology. 2008; 28(5):507-15. DOI: 10.1111/j.1440-1789.2008.00911.x. View

Maquoi E, Frankenne F, Baramova E, Munaut C, Sounni N, Remacle A . Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem. 2001; 275(15):11368-78. DOI: 10.1074/jbc.275.15.11368. View

Rao J . Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003; 3(7):489-501. DOI: 10.1038/nrc1121. View

Guo P, Imanishi Y, Cackowski F, Jarzynka M, Tao H, Nishikawa R . Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol. 2005; 166(3):877-90. PMC: 1602359. DOI: 10.1016/s0002-9440(10)62308-5. View

Inamoto T, Azuma H, Sakamoto T, Kiyama S, Ubai T, Kotake Y . Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1/2 inducible matrix metalloproteinases. Cancer Invest. 2007; 25(7):574-83. DOI: 10.1080/07357900701522471. View

Lee S, Park S, Cho Y, Park K, Kim E, Jung K . Activation of matrix metalloproteinase-9 by TNF-alpha in human urinary bladder cancer HT1376 cells: the role of MAP kinase signaling pathways. Oncol Rep. 2008; 19(4):1007-13. View

10.

Kunapuli P, Kasyapa C, Hawthorn L, Cowell J . LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem. 2004; 279(22):23151-7. DOI: 10.1074/jbc.M314192200. View

11.

Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H . Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol. 1999; 154(2):417-28. PMC: 1850004. DOI: 10.1016/S0002-9440(10)65288-1. View

12.

Stamenkovic I . Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2001; 10(6):415-33. DOI: 10.1006/scbi.2000.0379. View

13.

Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y . Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2005; 231(1):20-7. DOI: 10.1177/153537020623100103. View

14.

Bhaskara V, Panigrahi M, Challa S, Prakash Babu P . Comparative status of activated ERK1/2 and PARP cleavage in human gliomas. Neuropathology. 2005; 25(1):48-53. DOI: 10.1111/j.1440-1789.2004.00585.x. View

15.

Shim K, Jung S, Joo Y, Yoo K . Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007; 42(2):120-8. DOI: 10.1007/s00535-006-1975-y. View

16.

Lee K, Shin S, Kim K, Kim M, Hyun M, Kim T . Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep. 2006; 16(4):823-30. View

17.

Jelinek T, Dent P, Sturgill T, Weber M . Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Mol Cell Biol. 1996; 16(3):1027-34. PMC: 231085. DOI: 10.1128/MCB.16.3.1027. View

18.

Misugi F, Sumi T, Okamoto E, Nobeyama H, Hattori K, Yoshida H . Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int J Mol Med. 2005; 16(4):541-6. View

19.

Stetler-Stevenson W, Hewitt R, Corcoran M . Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996; 7(3):147-54. DOI: 10.1006/scbi.1996.0020. View

20.

Curran S, Murray G . Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999; 189(3):300-8. DOI: 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C. View